SOM Biotech Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 7

SOM Biotech General Information

Description

Developer of drugs designed for the treatment of rare and critical diseases. The company's artificial intelligence-based drug discovery technology allows for reducing costs and time in drug development, provide a high level of success and reliable patent protection, and engaging in the development of candidates, drug pipelines, and compounds to treat diseases, enabling the medical community to optimally combat acute and life-threatening diseases while maintaining safety and tolerance standards.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Carrer de Baldiri Reixac, 4
  • 08028 Barcelona
  • Spain
+34 934
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Carrer de Baldiri Reixac, 4
  • 08028 Barcelona
  • Spain
+34 934

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SOM Biotech Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Secondary Transaction - Private Completed Clinical Trials - Phase 3
10. Later Stage VC (Series B) 03-Nov-2023 Completed Clinical Trials - Phase 3
9. Later Stage VC (Series A) 01-Jan-2021 Completed Clinical Trials - Phase 3
8. Later Stage VC 08-Mar-2019 Completed Clinical Trials - Phase 3
7. Later Stage VC 01-Jul-2017 Completed Clinical Trials - Phase 3
6. Product Crowdfunding 02-Feb-2016 Completed Startup
5. Later Stage VC 07-Aug-2015 Completed Startup
4. Grant 10-Oct-2013 Completed Startup
3. Grant 30-Oct-2012 $389K $992K Completed Startup
2. Grant 13-Sep-2012 $528K $992K Completed Startup
To view SOM Biotech’s complete valuation and funding history, request access »

SOM Biotech Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary Shares
Ordinary Shares
Ordinary Shares 101,648 $0.011326 $8.56 $8.56 1x $8.56 0.19%
To view SOM Biotech’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

SOM Biotech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of drugs designed for the treatment of rare and critical diseases. The company's artificial intelligence-based
Drug Discovery
Barcelona, Spain
15 As of 2026

Cambridge, United Kingdom
 

Oxford, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SOM Biotech Competitors (4)

One of SOM Biotech’s 4 competitors is Healx, a Venture Capital-Backed company based in Cambridge, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Healx Venture Capital-Backed Cambridge, United Kingdom
Exscientia Formerly VC-backed Oxford, United Kingdom
BenevolentAI Formerly PE-Backed Luxembourg, Luxembourg
Recursion Pharmaceuticals Formerly VC-backed Salt Lake City, UT
To view SOM Biotech’s complete competitors history, request access »

SOM Biotech Patents

SOM Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026175555-A1 Pharmaceutical composition comprising bevantolol for the treatment of mental disorders Pending 18-Feb-2025
AU-2023222467-A1 Compounds for use in the treatment of dystrophinopathies Pending 21-Feb-2022
EP-4230196-A1 Compounds for use in the treatment of dystrophinopathies Inactive 21-Feb-2022
EP-4482481-A1 Compounds for use in the treatment of dystrophinopathies Active 21-Feb-2022
EP-4482481-B1 Compounds for use in the treatment of dystrophinopathies Active 21-Feb-2022 A61K31/4402
To view SOM Biotech’s complete patent history, request access »

SOM Biotech Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SOM Biotech Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Prevail Partners Venture Capital Minority
Additio Investment Group Venture Capital Minority
Convergence Partners (Switzerland) Venture Capital Minority
Health Technology Holding Venture Capital Minority
Monte Carlo Capital Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

SOM Biotech FAQs

  • When was SOM Biotech founded?

    SOM Biotech was founded in 2009.

  • Where is SOM Biotech headquartered?

    SOM Biotech is headquartered in Barcelona, Spain.

  • What is the size of SOM Biotech?

    SOM Biotech has 15 total employees.

  • What industry is SOM Biotech in?

    SOM Biotech’s primary industry is Drug Discovery.

  • Is SOM Biotech a private or public company?

    SOM Biotech is a Private company.

  • What is SOM Biotech’s current revenue?

    The current revenue for SOM Biotech is .

  • How much funding has SOM Biotech raised over time?

    SOM Biotech has raised $48.1M.

  • Who are SOM Biotech’s investors?

    Prevail Partners, Additio Investment Group, Convergence Partners (Switzerland), Health Technology Holding, and Monte Carlo Capital are 5 of 7 investors who have invested in SOM Biotech.

  • Who are SOM Biotech’s competitors?

    Healx, Exscientia, BenevolentAI, and Recursion Pharmaceuticals are competitors of SOM Biotech.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process